18.46
-0.79 (-4.10%)
| Previous Close | 19.25 |
| Open | 17.08 |
| Volume | 1,437,362 |
| Avg. Volume (3M) | 726,655 |
| Market Cap | 982,569,408 |
| Price / Earnings (TTM) | 14.42 |
| Price / Earnings (Forward) | 78.12 |
| Price / Sales | 2.53 |
| Price / Book | 2.41 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2026 |
| Profit Margin | 17.92% |
| Operating Margin (TTM) | -9.46% |
| Diluted EPS (TTM) | 1.12 |
| Quarterly Revenue Growth (YOY) | 17.50% |
| Total Debt/Equity (MRQ) | 7.98% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | 26.78 M |
| Levered Free Cash Flow (TTM) | 29.89 M |
| Return on Assets (TTM) | -5.20% |
| Return on Equity (TTM) | 19.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | CareDx, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.75 |
|
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 3.22% |
| % Held by Institutions | 99.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bamco Inc /Ny/ | 31 Dec 2025 | 3,155,180 |
| Deerfield Management Company, L.P. | 31 Dec 2025 | 2,191,000 |
| Ark Investment Management Llc | 31 Dec 2025 | 2,136,403 |
| Gagnon Securities Llc | 31 Dec 2025 | 1,774,890 |
| Braidwell Lp | 31 Dec 2025 | 1,585,220 |
| Sumitomo Mitsui Trust Group, Inc. | 31 Dec 2025 | 1,446,616 |
| Amova Asset Management Americas, Inc. | 31 Dec 2025 | 1,446,616 |
| Chevy Chase Trust Holdings, Llc | 31 Dec 2025 | 1,081,342 |
| 52 Weeks Range | ||
| Median | 21.00 (13.76%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 25 Feb 2026 | 21.00 (13.76%) | Hold | 18.46 |
| 15 Dec 2025 | 18.00 (-2.49%) | Hold | 19.91 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings |
| 27 Jan 2026 | Announcement | CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference |
| 12 Jan 2026 | Announcement | CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results |
| 07 Jan 2026 | Announcement | CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response |
| 26 Dec 2025 | Announcement | CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |